Drugs / bone marrow mononucleated cells
bone marrow mononucleated cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01089387 | May 2010 → May 2012 | erectile dysfunction, prostate cancer | French National Institute of Health and Medical Research | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bone marrow mononucleated cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01089387 ↗ |
| Known as | BM-MNCs | “intracavernous injection of bone marrow mononuclear cells (BM-MNCs) as a promising treatment approach for pRP-ED.” PMID 26439886 ↗ Oct 2015 |
| Known as | BMMNC | “Bone marrow mononucleated cells (BMMNC) contain different cell types that may replace the damaged penile cells after radical prostatectomy.” NCT01089387 ↗ |
| Known as | bone marrow mononuclear cells | “intracavernous injection of bone marrow mononuclear cells (BM-MNCs) as a promising treatment approach for pRP-ED.” PMID 26439886 ↗ Oct 2015 |
| Route | Other | “Intracavernous injection of BMMNC may therefore find application in the treatment of post prostatectomy erectile dysfunction.” NCT01089387 ↗ |